WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (NASDAQ:INCY) presented positive long-term clinical results today from an ongoing open-label Phase II trial for INCB18424, its selective, oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET). PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs). The data showing long-term clinical activity, including reduction in spleen size, phlebotomy independence (in PV patients) and improvement in blood counts lasting up to 27 months, were presented in an oral session (Abstract #313) at the 52nd American Society Hematology Annual Meeting in Orlando, FL. (ASH PV/ET Presentation)
